This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Diabetes Heart Failure Outcomes 
Heart BMJ
MARCH 26, 2025
Background Heart failure with preserved ejection fraction is a recognised outcome in patients with myocardial infarction, although heart failure with reduced ejection fraction is more common. fold higher risk of heart failure with preserved ejection fraction (95% CI 1.30 m/s had a 2.10-fold
52 
DAIC
MARCH 26, 2025
Food and Drug Administration (FDA) accepted its supplemental new drug application (sNDA) and granted Priority Review designation for KERENDIA(finerenone) for the treatment of adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).
Heart BMJ
MARCH 26, 2025
Heart failure (HF) is one of the significant complications in patients with myocardial infarction (MI), leading to increased risk for cardiovascular morbidity and mortality. 2 Therefore, early identification of HF in high-risk populations, particularly post-MI, is essential for improving outcomes. HFrEF is more commonly.
DAIC
MARCH 25, 2025
Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).
HCPLive
MARCH 31, 2025
Justin Mark, MD, discusses an analysis of the FIGHT trial looking at racial and ethnic differences in heart failure outcomes.
Cardiovascular Diabetology
JANUARY 19, 2024
Diabetes mellitus (DM) is associated with a worse prognosis in patients with heart failure. Our aim was to analyze the clinical and imaging features of patients with DM and their association with outcomes in c.
95 
European Journal of Heart Failure
OCTOBER 9, 2024
Cardiovascular outcomes with exenatide in type 2 diabetes (T2D) according to left ventricular ejection fraction (LVEF): the EXSCEL trial. CI, confidence interval; CVD, cardiovascular disease; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HHF, hospitalization for heart failure; HR, hazard ratio; NYHA, New York Heart Association.
75 
Circulation
FEBRUARY 12, 2024
BACKGROUND:Cardiovascular disease is a major cause of morbidity and mortality in patients with type 2 diabetes. The effects of glucose-lowering medications on cardiovascular outcomes in individuals with type 2 diabetes and low cardiovascular risk are unclear. years, type 2 diabetes duration of 4.0±2.7 0.86];P=0.022).
80 
Cardiovascular Diabetology
AUGUST 6, 2024
Objective To explore trends in prognosis and use of glucose-lowering drugs (GLD) in patients with diabetes and coronary artery disease (CAD). Research design and methods All patients with diabetes and CAD undergoing a coronary angiography between 2010 and 2021 according to the Swedish Angiography and Angioplasty Registry were included.
DAIC
APRIL 9, 2024
Decline in exercise ability is a hallmark of progression to overt heart failure. The international ARISE-HF trial was designed to test the effectiveness of the investigational drug AT-001 at stabilizing exercise capacity in patients with diabetic cardiomyopathy. Patients had had Type 2 diabetes for an average of 14 years.
Cardiovascular Diabetology
JUNE 6, 2024
Sodium glucose cotransporter 2 (SGLT2) inhibitors significantly improve cardiovascular outcomes in diabetic patients; however, the mechanism is unclear. We hypothesized that dapagliflozin improves cardiac outc.
64 
American College of Cardiology
NOVEMBER 7, 2024
The goal of the EMPEROR-Preserved trial was to assess the safety and efficacy of empagliflozin in patients with symptomatic heart failure with preserved ejection fraction (HFpEF), irrespective of diabetes status.
Cardiovascular Diabetology
APRIL 28, 2024
Glycemic control, as measured by glycosylated hemoglobin (HbA1c), is an important biomarker to evaluate diabetes severity and is believed to be associated with heart failure development. Type 2 diabetes mellit.
DAIC
APRIL 6, 2024
While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24,
European Journal of Heart Failure
NOVEMBER 26, 2024
Discontinuation and reinitiation of mineralocorticoid receptor antagonists (MRA) in patients with heart failure and reduced ejection fraction (HFrEF). BMI, body mass index; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association. 1.34), ischaemic heart disease (HR 1.20, 95% CI 1.09–1.31),
MIBHS
MARCH 31, 2025
Preventing Heart Attacks and Cardiac Arrest Maintaining a healthy lifestyle can reduce the risk of both heart attack and cardiac arrest. Visiting the emergency room at the first sign of a heart attack can help begin treatment quickly and prevent complications like heart failure.
DAIC
MARCH 25, 2025
Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).
HeartRhythm
APRIL 30, 2024
We have previously shown an association between metabolic syndrome (MS) and heart failure (HF) outcomes in patients with implanted defibrillators (ICD) and cardiac resynchronization therapy (CRT-D). However, the role of MS and diabetes in predicting HF outcomes was not assessed in non-obese patients.
Open Heart
MAY 23, 2024
Background and aims Pre-eclampsia complicates 3–5% of pregnancies worldwide and is associated with adverse outcomes for the mother and the offspring. Pre-eclampsia and heart failure have common risk factors, including hypertension, obesity and diabetes.
DAIC
APRIL 6, 2024
However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes.
European Journal of Heart Failure
FEBRUARY 25, 2025
Sodiumglucose cotransporter 2 (SGLT2) inhibitors in acute heart failure. Aims Results from randomized trials suggest benefit of sodiumglucose cotransporter 2 (SGLT2) inhibitor initiation in clinically stable acute heart failure. Follow-up started from discharge for maximum 1 year. There were 9641 eligible individuals.
Journal of the American Heart Association
MARCH 26, 2025
Journal of the American Heart Association, Ahead of Print. BackgroundBoth diabetes and low magnesiumcontaining food intake may increase the risk of heart failure (HF). The primary outcome was incident HF. These findings should be replicated in randomized controlled trials.
Journal of the American Heart Association
FEBRUARY 8, 2025
BackgroundClinical trials showed that glucagonlike peptide1 receptor agonist (GLP1RA) significantly improved the control of diabetes and reduced body weight compared with dipeptidyl peptidase 4 inhibitor (DPP4i). Primary outcome was 12month incidence of allcause death. Secondary outcome was hospitalization.
Cardiovascular Diabetology
OCTOBER 31, 2024
The association between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM) is unclear. This study aimed to investigate.
52 
Cardiovascular Diabetology
FEBRUARY 16, 2025
Obesity is common in the heart failure (HF) population and is regarded as an important risk factor for developing HF. Greater skeletal muscle mass has shown to be the underlying protective factor against cardi.
CardiacWire
AUGUST 2, 2024
Lilly’s blockbuster GLP-1 tirzepatide appears poised to become the next major HFpEF drug, after topline results from the SUMMIT trial showed that it significantly improved both outcomes and symptoms among patients with heart failure with preserved ejection fraction and obesity. vs. +15 KCCQ-CSS points). vs. -2.2%).
59 
Cardiovascular Diabetology
JULY 9, 2024
To adapt risk prediction equations for myocardial infarction (MI), stroke, and heart failure (HF) among patients with type 2 diabetes in real-world settings using cross-institutional electronic health records.
European Journal of Heart Failure
JANUARY 10, 2025
Abstract Aims In VERTIS CV, ertugliflozin was associated with a 30% risk reduction for adjudication-confirmed, first and total hospitalizations for heart failure (HHF) in participants with type 2 diabetes and atherosclerotic cardiovascular disease.
Circulation: Heart Failure
NOVEMBER 25, 2024
Circulation: Heart Failure, Volume 17, Issue 12 , Page e011629, December 1, 2024. Spironolactone, a steroidal mineralocorticoid receptor antagonist (MRA), has been used to treat patients with heart failure (HF) for more than half a century. The use of MRAs has been limited due to excessive concern about hyperkalemia.
Circulation
MARCH 9, 2025
Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidney disease, or heart failure, as well as among adults with few cardiovascular risk factors. Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025.
Frontiers in Cardiovascular Medicine
JANUARY 15, 2024
This systematic review of the literature aims to explore outcomes in the patients treated with conservative management vs. invasive strategy. The overall prevalence of arterial hypertension was 33.2%, hyperlipidemia, 26.9%, smoking, 17.8%, and diabetes, 3.9%. The overall mean age was 49.12 +/− 3.41, and 88% were females.
75 
The British Journal of Cardiology
AUGUST 6, 2024
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to reduce cardiovascular rehospitalisation in heart failure with reduced ejection fraction (HFrEF) patients. A retrospective study of four hospitals in England involving 184 patients with HFrEF exacerbations between March 2021 and June 2022 was performed.
40 
HeartRhythm
JANUARY 23, 2025
The prevalence of atrial fibrillation (AF) in patients with type 2 diabetes mellitus (T2DM) is reported to be higher than in the general population, ranging from 3.6% Also, the coexistence of T2DM and AF increases the risk of adverse cardiovascular events, including heart failure, atherosclerotic cardiovascular disease and mortality [2].
Hypertension Journal
NOVEMBER 22, 2023
BACKGROUND:Diabetes is an important risk factor for heart failure (HF) and is associated with left ventricular (LV) diastolic dysfunction. However, diabetic comorbid conditions, such as nocturnal hypertension, as predictors of diastolic dysfunction are not known in the absence of an HF period. Hypertension, Ahead of Print.
40 
Circulation: Cardiovascular Quality & Outcomes
FEBRUARY 8, 2024
Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. Background:Patients with type 2 diabetes are at risk of heart failure hospitalization. Accounting for all-cause mortality, we obtained the incidence for heart failure hospitalization at 5 years follow-up; overall and in each SDI group.
European Journal of Heart Failure
SEPTEMBER 26, 2023
Abstract Diagnosing heart failure is often difficult due to the non-specific nature of symptoms, which can be caused by a range of medical conditions. Natriuretic peptides (NPs) have been recognized as important biomarkers for diagnosing heart failure. Use of this acronym would enable the early diagnosis of heart failure.
Journal of Cardiovascular Electrophysiology
MARCH 3, 2025
ABSTRACT Background Atrial fibrillation (AF) recurrence remains a significant challenge in heart failure with reduced ejection fraction (HFrEF) patients undergoing cryoballoon ablation (CBA). This study assesses the impact of SGLT2i on AF recurrence and clinical outcomes in HFrEF patients undergoing CBA. vs. 39.4%, p =0.036).
Heart BMJ
DECEMBER 15, 2023
Aims Identifying clinical and echocardiographic parameters associated with improvement in systolic function in outpatients with heart failure with reduced ejection fraction (HFrEF) could lead to more targeted treatment improving systolic function and outcome. Beta-coefficients (β-coef) are standardised. to 7.51, p=0.006).
Heart BMJ
JANUARY 10, 2024
Objective Identification of patients at risk of adverse outcome from heart failure (HF) at an early stage is a priority. Primary outcome was a composite of first hospitalisation for HF or all-cause mortality. Log-transformed GDF-15 was the strongest predictor of outcome (HR 2.12, 95% CI 1.71
Cardiovascular Diabetology
FEBRUARY 18, 2025
Chronic thromboembolic pulmonary hypertension (CTEPH) is a severely progressive disease that leads to right heart failure and death. Previous studies have shown that diabetes and insulin resistance (IR) are cl.
52 
Cardiovascular Diabetology
OCTOBER 21, 2024
The therapeutic effects of ertugliflozin, a sodium-glucose cotransporter 2 inhibitor, on cardiovascular outcome are not fully understood. This study aimed to evaluate the efficacy and safety of ertugliflozin o.
Open Heart
JULY 20, 2022
Aims Heart failure (HF) is associated with comorbidities which independently influence treatment response and outcomes. Methods Patients acted as their own controls, with outcomes compared for equal periods (for each patient) pre (HF MDT) versus post-MDT (multispecialty) meeting. Results 334 patients (mean age 72.5±11
Circulation
NOVEMBER 11, 2024
Background:Heart failure (HF) is one of the leading causes of hospitalizations in the States. Patients with hyperkalemia had a higher frequency of diabetes mellitus, hypertension, chronic liver disease, acute kidney injury, chronic kidney disease, end-stage renal disease, and acute encephalopathy (p<0.001). 2], p<0.001).Conclusion:Hyperkalemia
40 
American College of Cardiology
APRIL 10, 2024
What are the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction (HFpEF) with and without diabetes, and consistency across key patient subgroups?
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content